Metabolic interactions between cysteamine and epigallocatechin gallate

Phase II clinical trials indicate that the combination of cysteamine plus epigallocatechin gallate (EGCG) is effective against cystic fibrosis in patients bearing the most frequent etiological mutation (CFTRΔF508). Here, we investigated the interaction between both agents on cultured respiratory epi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Cycle
Main Authors: Izzo, Valentina, Pietrocola, Federico, Sica, Valentina, Durand, Sylvère, Lachkar, Sylvie, Enot, David, Bravo-San Pedro, José Manuel, Chery, Alexis, Esposito, Speranza, Raia, Valeria, Maiuri, Luigi, Maiuri, Maria Chiara, Kroemer, Guido
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5323035/
https://ncbi.nlm.nih.gov/pubmed/28059601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2016.1249550
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados